Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 260

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

Open access
Palma, David A., Olson, Robert, Harrow, Stephen, Correa, Rohann J. M., Schneiders, Famke, Haasbeek, Cornelis J. A., Rodrigues, George B., Lock, Michael, Yaremko, Brian P., Bauman, Glenn S., Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J., de Gruijl, Tanja D., Allan, Alison, Senan, Suresh · 2019 · BMC Cancer

Abstract

BACKGROUND: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a group of patients with a small burden of oligometastatic disease (mostly with 1-3 metastatic lesions), and found that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial is to assess the impact of SABR in patients with 4-10 metastatic cancer lesions. METHODS: One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-specified systemic therapy (Group 1: immunotherapy/targeted; Group 2: cytotoxic; Group 3: observation). SABR is to be completed within 2 weeks, allowing for rapid initiation of systemic therapy. Recommended SABR doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, chosen to minimize risks of toxicity. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, time to development of new metastatic lesions, quality of life, and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. DISCUSSION: This study will provide an assessment of the impact of SABR on clinical outcomes and quality of life, to determine if long-term survival can be achieved for selected patients with 4-10 oligometastatic lesions. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03721341 . Date of registration: October 26, 2018.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-019-5977-6

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 260

Metadata

Authors
Palma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., Ahmad, B., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Mulroy, L., Senthi, S., Louie, A. V., Swaminath, A., Chalmers, A., Warner, A., Slotman, B. J., de Gruijl, T. D., Allan, A., & Senan, S.
Venue
BMC Cancer
Published
2019-08-19
Volume
19
Issue
1
Pages
816-816
ISSN
1471-2407 (ISSN-L)
OpenAlex
W4232184817
Cited by
260
References
29
FWCI
28.95
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. https://app.cochat.ai/papers/10.1186/s12885-019-5977-6
The paper
Palma, D. A., Olson, R., Harrow, S., Correa, R. J. M., Schneiders, F., Haasbeek, C. J. A., Rodrigues, G. B., Lock, M., Yaremko, B. P., Bauman, G. S., Ahmad, B., Schellenberg, D., Liu, M., Gaede, S., Laba, J., Mulroy, L., Senthi, S., Louie, A. V., Swaminath, A., . . . Senan, S. (2019). Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. https://doi.org/10.1186/s12885-019-5977-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.